Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus Aureus Isolated From Hospitalized Patients

Overview

Journal Ann Lab Med

Specialty Pathology

Date 2016 Feb 27

PMID 26915612

Citations 5

Authors

Young Rae Koh

Kye Hyung Kim

Chulhun L Chang

Jongyoun Yi

Affiliations

Soon will be listed here.

Abstract

Background: We estimated the prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). The concordance between macromethod and glycopeptide resistance detection (GRD) E tests was determined. In addition, predictors of clinical outcomes in hospitalized patients with S. aureus bacteremia (SAB) or pneumonia (SAP) were evaluated.

Methods: We obtained 229 consecutive S. aureus isolates from all hospitalized patients at two university hospitals located in Busan and Yangsan, Korea. Standard, macromethod, and GRD E tests were performed. Additionally, we reviewed the medical records of all patients. Among the 229 patients, predictors of clinical outcomes were analyzed for 107 patients with SAB and 39 with SAP.

Results: Among the 229 isolates, 34.5% of S. aureus isolates and 50.7% of methicillin-resistant S. aureus isolates exhibited the hVISA phenotype based on the macromethod E test. hVISA was nearly associated with treatment failure in patients with SAB (P=0.054) and was significantly associated with treatment failure in patients with SAP (P=0.014). However, hVISA was not associated with 30-day mortality in patients with SAB or SAP. The concordance between the macromethod and GRD E tests was 84.2%.

Conclusions: hVISA is quite common in the southeastern part of Korea. hVISA is associated with treatment failure in patients with SAP.

Citing Articles

Improving the Work Efficiency of Therapeutic Drug Monitoring Reports Through the Establishment of an Automated Data Transfer System.

Lee S, Yoon S, Kim H, Kim S, Lee W, Chun S Ann Lab Med. 2023; 43(6):628-631.

PMID: 37387497 PMC: 10345171. DOI: 10.3343/alm.2023.43.6.628.

Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci.

Dao T, Alsallaq R, Parsons J, Ferrolino J, Hayden R, Rubnitz J Antimicrob Agents Chemother. 2020; 64(11).

PMID: 32816729 PMC: 7577166. DOI: 10.1128/AAC.00944-20.

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Shariati A, Dadashi M, Moghadam M, van Belkum A, Yaslianifard S, Darban-Sarokhalil D Sci Rep. 2020; 10(1):12689.

PMID: 32728110 PMC: 7391782. DOI: 10.1038/s41598-020-69058-z.

Recent pattern of antibiotic resistance in clinical isolates in Eastern India and the emergence of reduced susceptibility to vancomycin.

Mohanty S, Behera B, Sahu S, Praharaj A J Lab Physicians. 2020; 11(4):340-345.

PMID: 31929701 PMC: 6943858. DOI: 10.4103/JLP.JLP_39_19.

Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.

Lai C, Chen C, Chuang Y, Tang H Sci Rep. 2017; 7:41758.

PMID: 28139739 PMC: 5282487. DOI: 10.1038/srep41758.

References

Kullar R, Davis S, Levine D, Rybak M . Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011; 52(8):975-81. DOI: 10.1093/cid/cir124. View

Satola S, Farley M, Anderson K, Patel J . Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2010; 49(1):177-83. PMC: 3020420. DOI: 10.1128/JCM.01128-10. View

Kim M, PAI C, Woo J, Ryu J, Hiramatsu K . Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol. 2000; 38(10):3879-81. PMC: 87500. DOI: 10.1128/JCM.38.10.3879-3881.2000. View

Mylotte J, Tayara A . Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis. 2000; 31(5):1170-4. DOI: 10.1086/317421. View

Wootton M, Howe R, Hillman R, Walsh T, Bennett P, MacGowan A . A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001; 47(4):399-403. DOI: 10.1093/jac/47.4.399. View

Hiramatsu K . Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2002; 1(3):147-55. DOI: 10.1016/S1473-3099(01)00091-3. View

Kim M, Hwang S, Mun H, Pai C . Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol. 2002; 40(4):1376-80. PMC: 140376. DOI: 10.1128/JCM.40.4.1376-1380.2002. View

Cui L, Ma X, Sato K, Okuma K, Tenover F, Mamizuka E . Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 2003; 41(1):5-14. PMC: 149586. DOI: 10.1128/JCM.41.1.5-14.2003. View

Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View

10.

Liu C, Chambers H . Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003; 47(10):3040-5. PMC: 201119. DOI: 10.1128/AAC.47.10.3040-3045.2003. View

11.

Sieradzki K, Tomasz A . Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol. 2003; 185(24):7103-10. PMC: 296238. DOI: 10.1128/JB.185.24.7103-7110.2003. View

12.

Charles P, Ward P, Johnson P, Howden B, Grayson M . Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3):448-51. DOI: 10.1086/381093. View

13.

Howden B, Ward P, Charles P, Korman T, Fuller A, du Cros P . Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38(4):521-8. DOI: 10.1086/381202. View

14.

Lew D, Waldvogel F . Osteomyelitis. Lancet. 2004; 364(9431):369-79. DOI: 10.1016/S0140-6736(04)16727-5. View

15.

Horan T, Gaynes R, Martone W, Jarvis W, Emori T . CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992; 13(10):606-8. View

16.

Durack D, Lukes A, Bright D . New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med. 1994; 96(3):200-9. DOI: 10.1016/0002-9343(94)90143-0. View

17.

Hiramatsu K, Hanaki H, Ino T, YABUTA K, Oguri T, Tenover F . Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40(1):135-6. DOI: 10.1093/jac/40.1.135. View

18.

Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S . Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092):1670-3. DOI: 10.1016/S0140-6736(97)07324-8. View

19.

Harbarth S, Rutschmann O, Sudre P, Pittet D . Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med. 1998; 158(2):182-9. DOI: 10.1001/archinte.158.2.182. View

20.

Smith T, Pearson M, WILCOX K, Cruz C, Lancaster M, Robinson-Dunn B . Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340(7):493-501. DOI: 10.1056/NEJM199902183400701. View